A Relevance Study Between the Result of Clinical Drug Intervention and Next-generation Sequencing Technology Focused on Refractory Helicobacter Pylori Infection

Summary

Approximately 50% of people in the world are infected with H. pylori, and its eradication rate fail to exceed 80% and even fails into an unacceptable range.Various risk factors for infection include lower socioeconomic status, younger age, and geographic location.In the present study, investigators aimed to perform a prevalence survey about risk factors for H. pylori infection.To obtain the higher eradication of H. pylori and find out the relevance between the diverse infection and clinical drug focused on refractory H. pylori infection.

Conditions

• Gastritis

Interventions

DEVICE

The eradication times of the patients

The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group

DEVICE

The result of 13C-urea breath test after treatment

The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.

Sponsors & Collaborators

• People Hospital of Luohu,Shenzhen

  collaborator UNKNOWN

• Shenzhen Second People's Hospital

  collaborator OTHER

• Longhua Branch of Shenzhen People Hospital

  collaborator UNKNOWN

• The People Hospital of Baoan Shenzhen

  collaborator OTHER

• Zhiyuan Medical Inspection Institute

  collaborator OTHER

• The University of Hong Kong-Shenzhen Hospital

  lead OTHER

Principal Investigators

• Tao Lyu, Doctor · The University of HongKong-Shenzhen Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-07-31

Primary Completion

2019-06-30

Completion

2019-12-31

Countries

• China

Study Locations